missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CD105 Monoclonal Antibody (MEM-229)
Mouse Monoclonal Antibody
Brand: Invitrogen™ MA119408
This item is not returnable.
View return policy
Description
This antibody recognizes an extracellular epitope of CD105 (Endoglin), a 90 kDa type I integral membrane homodimer glycoprotein expressed on vascular endothelial cells (small and large vessels), activated monocytes and tissue macrophages, stromal cells of certain tissues including bone marrow, pre-B lymphocytes in fetal marrow and erythroid precursors in fetal and adult bone marrow; it is also present on syncytiotrophoblast on placenta throughout pregnancy. Western Blot: non-reducing conditions; Immunohistochemistry (Frozen): acetone fixation.
CD105 or Endoglin is a Type I transmembrane protein, which is highly expressed on human vascular endothelial cells. It exists on an O- and N-glycosylated homodimer. Up regulation of endoglin expression has been demonstrated in tumor vasculature and proliferating cells, suggesting that it is a proliferation associated endothelial marker. CD105 binds to TGF beta 1 and 3 with high affinity but not to TGF beta 2.
Specifications
| CD105 | |
| Monoclonal | |
| 1 mg/mL | |
| PBS with 15mM sodium azide; pH 7.4 | |
| P17813, P37176 | |
| ENG | |
| Recombinant Vaccinia virus containing human CD105 (L-isoform) cDNA. | |
| 100 μg | |
| Primary | |
| Human, Pig | |
| Antibody | |
| IgG2a |
| Flow Cytometry, Immunohistochemistry (Frozen), Western Blot, Immunocytochemistry | |
| MEM-229 | |
| Unconjugated | |
| ENG | |
| AI528660; AI662476; CD105; CD105 antigen; cell surface MJ7/18 antigen; Edg; END; Endo; Endoglin; endoglin (Osler-Rendu-Weber syndrome 1); Eng; HHT1; ORW; ORW1; S-endoglin; transmembrane glycoprotein | |
| Mouse | |
| Protein A | |
| RUO | |
| 2022, 397096 | |
| 4°C, do not freeze | |
| Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction